AlphAIAlphAI — Financial news for AI agents
rttnews.com$DH

Definitive Healthcare Names Clay Ritchey CEO, Succeeding Kevin Coop; Shares Up

Definitive Healthcare Corp. (DH) named Clay Ritchey as CEO and board member, effective September 8. Ritchey succeeds Kevin Coop, who left on August 31, 2026. Ritchey previously led Verato, Evariant, and other healthcare firms. DH shares rose 13.04% in pre-market trading.

Original reporting
rttnews.com
Published Sep 2, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 5:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$DH
Bullish
medium confidence
Mentioned
$DH
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$DHBullishLow
01

Why it matters

The appointment of Clay Ritchey, former CEO of Verato, is the first public disclosure and immediately moved the stock up 13% pre‑market.

02

Market read

Executive change with notable price reaction; short‑term trading opportunity but limited longer‑term impact without further guidance.

03

What to watch

Lack of disclosed strategic plan or financial guidance accompanying the appointment.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Definitive Healthcare (DH) provides data and analytics to the healthcare industry; leadership changes can affect product roadmap and partnerships.

Company-level read

Ticker impact

$DHBullishMedium confidence
Context

Definitive Healthcare announced new CEO Clay Ritchey, causing a 13% pre‑market price jump.

Expected impact

Potential continued upside if market views the appointment favorably; watch for volatility.

Evidence & confidence

First‑report executive change with immediate price reaction; limited longer‑term guidance.

Market effects

Sector

May signal confidence in healthcare data analytics sector, could lift peers.

Regional

U.S. Nasdaq healthcare‑tech stocks may see modest lift.

Global

Limited to U.S. market; no global macro effect.

Counterpoint

What could challenge this read

New CEO could bring strategic shifts that may not align with current investor expectations.

Key entities

  • person
    Clay Ritchey

    New CEO of Definitive Healthcare

  • person
    Kevin Coop

    Outgoing CEO

Read at source← All news

Related articles

$DHMed

Definitive Healthcare Reports Financial Results for Third Quarter 2026

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter 2026 Third Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (November 5, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),

SEC EDGAR 8-K
$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com
$DHMedAI 8/10

Advent Proposed $1.02 Cash Take-Private of Definitive Healthcare:

Definitive Healthcare Corp. (DH) received a non-binding take-private proposal from Advent International for $1.02 per share. The offer is subject to review by a special committee and requires founder Jason Krantz's equity rollover. No binding agreement exists yet, and Advent may withdraw or modify the proposal.

hedgeco.net
$DHMedAI 8/10

Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

fool.com
$DHHigh

Definitive Healthcare Reports Financial Results for Second Quarter 2026

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),

SEC EDGAR 8-K